John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients

被引：10

作者：

van Kempen, Z. L. E. ^{[1
]}

Leurs, C. E. ^{[1
]}

de Vries, A. ^{[2
]}

Vennegoor, A. ^{[1
]}

Rispens, T. ^{[3
]}

Wattjes, M. P. ^{[4
]}

Killestein, J. ^{[1
]}

机构：

[1] Vrije Univ Amsterdam, Med Ctr, VUmc MS Ctr Amsterdam, Dept Neurol,Amsterdam Neurosci, Amsterdam, Netherlands

[2] Sanquin, Sanquin Diagnost Serv, Biol Lab, Amsterdam, Netherlands

[3] Sanquin Res & Landsteiner Lab, Dept Immunol, Amsterdam, Netherlands

[4] Vrije Univ Amsterdam, Med Ctr, VUmc MS Ctr Amsterdam, Dept Radiol & Nucl Med, Amsterdam, Netherlands

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2017年 / 24卷 / 09期

关键词：

JC virus; multiple sclerosis; natalizumab; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; ANTIBODY-LEVELS; SERUM; RISK; SEROCONVERSION; PLASMA; COHORT;

D O I：

10.1111/ene.13355

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background and purposeInfection with the John Cunningham virus (JCV) is required for the development of progressive multifocal leukoencephalopathy, the feared complication of natalizumab treatment in multiple sclerosis patients. The JCV seroconversion rate seems higher in natalizumab treated patients than in the normal population, with an unknown cause. MethodsNatalizumab concentration was correlated to JCV antibody status and seroconversion in a large cohort of multiple sclerosis patients. ResultsOne hundred and thirty-five patients were included. No correlation was found between natalizumab concentration and JCV status, JCV seroconversion or JCV index. ConclusionsHigher natalizumab concentrations do not explain the increased JCV seroconversion rate in natalizumab treated patients.

引用

页码：1196 / 1199

页数：4

共 50 条

[1] Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients
Dominguez-Mozo, M. I.
Garcia-Montojo, M.
Arias-Leal, A.
Garcia-Martinez, A.
Santiago, J. L.
Casanova, I.
Galan, V.
Arroyo, R.
Fernandez-Arquero, M.
Alvarez-Lafuente, R.
EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 (01) : 182 - 189
[2] Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis
Gelissen, Liza M. Y.
Toorop, Alyssa A.
Schipper, Pien M.
Hoitsma, Elske
Zeinstra, Esther M. P. E.
van Rooij, Luuk C.
van Munster, Caspar E. P.
Vennegoor, Anke
Mostert, Jop
Wokke, Beatrijs
Kalkers, Nynke F.
Hoogervorst, Erwin L. J.
van Eijk, Jeroen
Roosendaal, Christiaan M.
Kragt, Jolijn J.
Eurelings, Marijke
van Genugten, Jessie
Nielsen, Jessica
Sinnige, L. G. F.
Kloosterziel, Mark E.
Arnoldus, Edo P. J.
Bouvy, Willem H.
Strijbis, Eva M.
van Oosten, Bob
De Jong, Brigit A.
Uitdehaag, Bernard M. J.
Lissenberg-Witte, Birgit, I
Loeff, Floris C.
Rispens, Theo
Killestein, Joep
van Kempen, Zoe L. E.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2025,
[3] Variability of John Cunningham virus (JCV) index in multiple sclerosis patients treated with natalizumab in routine clinical practice
Arndt, N.
Reder, A. T.
Javed, A.
MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 296 - 296
[4] Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis
Branco, Luciana Prats
Adoni, Torso
Apostolos-Pereira, Samira Luisa
Bidin Brooks, Joseph Bruno
Correa, Eber Castro
Damasceno, Carlos Augusto
Biondo Eboni, Audred Cristina
Fezer, Leticia
da Gama, Paulo Diniz
Magno Goncalves, Marcus Vinicius
Gomes, Sidney
Grzesiuk, Anderson Kuntz
Mendes, Maria Fernando
Morales, Rogerio Rizo
Muniz, Andre
Koncke Parolin, Monica Fiuza
Vellutini Pimentel, Maria Lucia
Ribeiro, Mortise de Castro
Cruz dos Santos, Gutemberg Augusto
Sato, Henry Koiti
Scherpenhuijzen, Simone Batista
Scorcine, Claudio
Siquineli, Fabio
de Carvalho Sousa, Nise Alexandra
Varela, Daniel Lima
Avila Winckler, Tereza Cristina
Fragoso, Yara Dadalti
ARQUIVOS DE NEURO-PSIQUIATRIA, 2018, 76 (09) : 588 - 591
[5] Frequency of John Cunningham virus (JCV) DNA and of antibodies against JCV in patients affected by multiple sclerosis and their relationship with natalizumab therapy
Lo Re, V.
Cardinale, F.
De Grazia, S.
Alessi, S.
Cusimano, V.
Mazzola, M. A.
Lo Re, M.
Realmuto, S.
Ragonese, P.
Salemi, G.
Conaldi, P.
Savettieri, G.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 463 - 463
[6] Humoral response to John Cunningham virus during pregnancy in multiple sclerosis
Saraste, M.
Atula, S.
Hedman, K.
Hurme, S.
Jalkanen, A.
Sneck, M.
Surcel, H. -M.
Maghzi, A. H.
Airas, L.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2018, 21 : 11 - 18
[7] A longitudinal study of John Cunningham (JC)virus serostatus stability among multiple sclerosis patients
Alroughani, Raed
Akhtar, Saeed
Ahmed, Samar
Al-Hashel, Jasem
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP6 - NP7
[8] Mutations in the John Cunningham virus VP1 gene could predispose to the development of progressive multifocal leukoencephalopathy in multiple sclerosis patients undergoing treatment with natalizumab
Flores, J.
Anguiano, O.
Rivas-Alonso, V.
Gonzalez-Conchillos, H.
Pererez-Saldivar, M.
Sotelo, J.
Maganana-Maldonado, R.
Quinones, S.
Corona, T.
Olivares, H.
Hernandez-Gonzalez, O.
Martinez-Palomo, A.
Trevino, I.
Ordonez, G.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 56
[9] Assay Selection Affects John Cunningham Virus Serostatus Classification in Multiple Sclerosis
Raffel, Joel B.
Hunt, David
Topping, Joanne
Bremner, John
Brown, Kevin E.
Giovannoni, Gavin
ANNALS OF NEUROLOGY, 2012, 72 (02) : 295 - 296
[10] JC virus in multiple sclerosis patients treated with natalizumab
Inmaculacla Dominguez-Mozo, Maria
Alvarez-Lafuente, Roberto
Garcia-Montojo, Marta
De las Heras, Virginia
Manuel Bartolome, Francisco
Arroyo, Rafael
MULTIPLE SCLEROSIS, 2008, 14 : S39 - S39

← 1 2 3 4 5 →